ESR1 and ovarian cancer: Because the growth response in ovarian cancer cell lines is mediated by ERα but not by ERβ [5,9], treatment with an ERα specific agonist (PTT,4′,4′,4′′- (4-(4-Propyl-[1H]-pyrazole-1,2,5-tryl)trisphenol) promotes cell proliferation [5].